Halozyme Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.5% | +43.9% | +98.8% | -15.3% | +28.5% | +2.5% | +90.4% | +66.7% | -5.9% | +19.1% | +22.4% | |
| – | +6.5% | +49.3% | +99.0% | -16.2% | +27.0% | +2.1% | +67.0% | -20.2% | +1.0% | +45.4% | -24.0% | |
| – | -29.5% | +54.2% | +152.7% | -65.7% | +107.4% | +22.9% | -19.6% | +97.3% | -49.5% | -2.1% | +15.5% | |
| – | -20.1% | +89.2% | +128.9% | -24.4% | +18.8% | -12.6% | +101.3% | -51.0% | -7.4% | +77.4% | -76.0% | |
| – | +254.2% | -51.6% | +41.2% | +35.6% | +98.1% | +64.4% | -6.9% | +154.0% | +1.4% | +31.7% | +43.1% | |
| – | +48.1% | +54.1% | -64.8% | +339.7% | +29.8% | +106.9% | -11.3% | +85.7% | +27.4% | +11.2% | +24.4% | |
| – | +33.6% | +8.1% | -17.4% | +112.1% | +45.4% | -2.4% | -17.0% | +759.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | +1.9% | +0.0% | +39.2% | |
| – | – | – | – | – | – | – | – | – | -13.5% | -15.0% | +144.2% | |
| – | +11.4% | +111.8% | +6.0% | -38.6% | +147.8% | -9.5% | +111.6% | +84.2% | -1.3% | +3.0% | +45.7% | |
| – | +156.7% | -12.6% | +140.6% | +13.7% | -42.7% | +392.1% | -72.2% | +11.6% | -14.0% | +23.7% | +27.3% | |
| – | -56.2% | -20.4% | +343.9% | +18.5% | -78.6% | +1,932.7% | -77.5% | -85.1% | -50.7% | – | – | |
| – | +49.8% | -20.5% | +122.1% | -48.7% | +57.7% | -70.0% | -20.1% | +1,048.2% | -33.2% | -13.3% | +103.9% | |
| – | -43.9% | +612.3% | -37.2% | -72.1% | +998.4% | – | – | +89.6% | +0.4% | +0.4% | +42.3% | |
| – | +4.0% | -175.5% | – | +19.4% | -63.1% | +64.6% | +30.4% | -13.8% | -50.6% | +334.1% | -86.6% | |
| – | – | – | – | – | – | – | – | – | -36.8% | +297.4% | -84.8% | |
| – | +3.3% | +1.0% | +8.7% | +3.3% | +0.5% | -2.0% | +3.8% | -4.2% | -4.6% | -3.6% | -4.3% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.